{"id":491041,"date":"2021-05-11T07:34:01","date_gmt":"2021-05-11T11:34:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-corporate-update\/"},"modified":"2021-05-11T07:34:01","modified_gmt":"2021-05-11T11:34:01","slug":"aslan-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-corporate-update\/","title":{"rendered":"ASLAN Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update"},"content":{"rendered":"
\n

\n \u00a0– Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021
<\/strong>
\n \u00a0–\u00a0Phase 2b clinical trial for ASLAN004 expected to initiate in the second half of 2021<\/strong>\n <\/p>\n

SINGAPORE, May 11, 2021 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2021 and provided an update on its clinical development activities.<\/p>\n

\n Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said<\/strong>: \u201cWe have continued to make solid progress in 2021 and we are on track to complete the expansion cohort in our multiple ascending dose trial for ASLAN004 with an additional 27 patients expected to be enrolled by mid-2021 followed by the announcement of topline data expected in the third quarter of 2021. We are excited to expand our senior management team with two highly experienced executives, Dr Karen Veverka, who will be leading our clinical development program, and Joseph Suttner to lead clinical operations. In addition, we are preparing for our Phase 2b trial for ASLAN004, which we expect to initiate in the second half of 2021. Our robust financial position provides the resources to fund development activities and achieve additional value creating milestones for shareholders.\u201d<\/em><\/p>\n

\n First quarter 2021 and recent business highlights<\/strong>\n <\/p>\n

\n Clinical development <\/em>\n <\/p>\n

\n ASLAN004<\/em>\n <\/p>\n